While Alzheimer’s disease is the most common type of dementia, there’s another variation that is also relatively prevalent. Lewy body dementia (LBD) affects more than 1 million people in the US. It is ...
Cognition Therapeutics, Inc. announced positive results from its Phase 2 trials of zervimesine (CT1812) in treating dementia with Lewy bodies (DLB) and Alzheimer’s disease, indicating significant ...
Cognition Therapeutics announces promising Phase 2 trial results for CT1812 in dementia with Lewy bodies, with plans for late-stage trials. Cognition Therapeutics, Inc. announced promising topline ...
A team of researchers at Johns Hopkins Medicine say they have revealed a possible molecular connection between air pollution and an increased risk of developing Lewy body dementia. Subscribe to our ...